Active substance
Piperacillin tazobactam
- US FDA 1
- US price lines 1
- Safety 3
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| PIPERACILLIN AND TAZOBACTAM | 0.375G; 3.0G; 0.5G/1VIAL; 4.0G; 4.5G; 36G; EQ 12GM BASE/VIAL;EQ 1.5GMBASE/VIAL; EQ 36GM BASE/VIAL;EQ 4.5GMBASE/VIAL | injection · powder,for solution | EUGIA PHARMA | Prescription | 12 Oct 2023 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | PIPERACIL-TAZOBACT 3.375 GM VL | $3.49257 | per EA | 21 Jan 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- EMA PRAC 30 Sep 2021 PRAC signal: Haemophagocytic lymphohistiocytosis
Action for MAH: update of the product information: Yes - EMA PRAC 9 Apr 2021 PRAC signal: Haemophagocytic lymphohistiocytosis
Action for MAH: update of the product information: No - MHRA 11 Dec 2014 Piperacillin/tazobactam: compatibility of generics is different from brand leader (tazocin)
Generic piperacillin/tazobactam products have different compatibilities with other medicines compared with tazocin, raising a risk of serious medication errors.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.